当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.

Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.

Abstract：

:The AML1 (RUNX1)-MTG8 (ETO) fusion transcription factor generated by the t(8;21) translocation is believed to deregulate the expression of genes that are crucial for normal differentiation and proliferation of hematopoietic progenitors, resulting in acute myelogenous leukemia. To elucidate the role of AML1-MTG8 in leukemogenesis, we used oligonucleotide microarrays to detect alterations in gene expression caused by ectopic expression of AML1-MTG8 in a murine myeloid progenitor cell line, L-G. Microarray analysis of approximately 6500 genes identified 32 candidate genes under the downstream control of AML1-MTG8. Among the 32 genes, 23 were not known to be regulated by AML1-MTG8. These included many granule protein genes and several cell surface antigen genes. Interestingly, AML1-MTG8 enhanced the expression of several genes that are usually induced during granulocytic differentiation, particularly those encoding azurophil granule proteins, including cathepsin G, myeloperoxidase and lysozyme. This indicates that AML1-MTG8 induces partial differentiation of myeloid progenitor cells into promyelocytes in the absence of the usual differentiation signals, while it inhibits terminal differentiation into mature granulocytes. Thus, AML1-MTG8 itself may play a crucial role in defining a unique cytologic type with abnormal maturation, characteristic of t(8;21) acute myelogenous leukemia.

journal_name

Leukemia

journal_title

Leukemia

authors

Shimada H,Ichikawa H,Ohki M

doi

10.1038/sj.leu.2402465

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

874-85

issue

5

eissn

0887-6924

issn

1476-5551

journal_volume

16

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • The MLL recombinome of acute leukemias in 2017.

    abstract：:Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present the data obtained from 2345 acute leukemia patients. Genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and 1...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.213

    authors： Meyer C,Burmeister T,Gröger D,Tsaur G,Fechina L,Renneville A,Sutton R,Venn NC,Emerenciano M,Pombo-de-Oliveira MS,Barbieri Blunck C,Almeida Lopes B,Zuna J,Trka J,Ballerini P,Lapillonne H,De Braekeleer M,Cazzaniga G,Cor

    更新日期：2018-02-01 00:00:00

  • Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.

    abstract：:Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whe...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Griffiths SD,Cawley JC

    更新日期：1988-06-01 00:00:00

  • The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.

    abstract：:Multiple myeloma is the second most frequent hematological cancer after lymphoma and remains an incurable disease. The pervasive support provided by the bone marrow microenvironment to myeloma cells is crucial for their survival. Here, an unbiased assessment of receptor tyrosine kinases overexpressed in myeloma identi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0486-9

    authors： Frenquelli M,Caridi N,Antonini E,Storti F,Viganò V,Gaviraghi M,Occhionorelli M,Bianchessi S,Bongiovanni L,Spinelli A,Marcatti M,Belloni D,Ferrero E,Karki S,Brambilla P,Martinelli-Boneschi F,Colla S,Ponzoni M,DePinho R

    更新日期：2020-01-01 00:00:00

  • Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia.

    abstract：:To determine the clinical relevance of in vitro drug chemoresistance in childhood acute myeloid leukemia, we used an MTT assay to test leukemic cells from 132 newly diagnosed children. Patients were diagnosed according to the French-American-British (FAB) classification as follows: M0 (n = 12), M1 (n = 16), M2 (n = 53...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402305

    authors： Yamada S,Hongo T,Okada S,Watanabe C,Fujii Y,Ohzeki T

    更新日期：2001-12-01 00:00:00

  • Cytokine enhancement of immunogenicity in chronic myeloid leukaemia.

    abstract：:Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic respon...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400858

    authors： Coleman S,Throp D,Fisher J,Bailey-Wood R,Lim SH

    更新日期：1997-12-01 00:00:00

  • Myeloid surface antigen expression in adult acute lymphoblastic leukemia.

    abstract：:The expression of myeloid surface markers was investigated in 41 cases of untreated adult acute lymphoblastic leukemia (ALL). Nineteen cases (46%) reacted with at least one myeloid monoclonal antibody (CD15 in 16 cases, CD13 in 10 cases, CD14 in five cases, and CD33 in four cases). Double-staining confirmed the coexpr...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Guyotat D,Campos L,Shi ZH,Charrin C,Treille D,Magaud JP,Fiere D

    更新日期：1990-09-01 00:00:00

  • A paradigm shift in myelodysplastic syndromes.

    abstract：:A poorly defined transforming event(s) affects the pluripotential bone marrow (BM) stem cell in myelodysplastic syndromes (MDS), conferring a growth advantage upon it which leads eventually to monoclonal hematopoiesis. The progeny of this transformed ancestor undergo recognizable albeit dysplastic maturation. We propo...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Raza A,Mundle S,Shetty V,Alvi S,Chopra H,Span L,Parcharidou A,Dar S,Venugopal P,Borok R,Gezer S,Showel J,Loew J,Robin E,Rifkin S,Alston D,Hernandez B,Shah R,Kaizer H,Gregory S,Preisler H

    更新日期：1996-10-01 00:00:00

  • Characterization of acute lymphoblastic leukemia of childhood by immunoglobulin and T-cell receptor gene patterns.

    abstract：:Molecular biological studies of immunoglobulin (Ig) and T-cell antigen receptor (TCR) genes provide novel approaches to the identification and characterization of the acute lymphoblastic leukemias (ALL). Such studies greatly enhance our understanding of both the cells of origin in these diseases and the order of assem...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Felix CA,Poplack DG

    更新日期：1991-12-01 00:00:00

  • Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia.

    abstract：:Three cell populations with different DNA indices were demonstrated in a case of biphenotypic terminal transferase (TdT)/myeloid-positive acute leukemia which had developed from a pre-leukemic diploid population also expressing biphenotypic features. At the time of development of acute leukemia, flow-cytometric analys...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Paietta E,Andreeff M,Papenhausen P,Gucalp R,Wiernik PH

    更新日期：1989-01-01 00:00:00

  • Expression of mRNA for serglycin core protein and other platelet alpha granule proteins is increased in human erythroleukemia cells by phorbol myristate acetate.

    abstract：:This study has determined the effects of phorbol-12-myristate-13-acetate (PMA) and dimethylsulfoxide (DMSO) on mRNA levels for the serglycin proteoglycan core protein in human erythroleukemia (HEL) cells. We have compared these changes to those for mRNA for other proteins which are known to be synthesized by HEL cells...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Schick BP,Thornton RD

    更新日期：1993-12-01 00:00:00

  • A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.

    abstract：:Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.191

    authors： Wierda WG,Castro JE,Aguillon R,Sampath D,Jalayer A,McMannis J,Prussak CE,Keating M,Kipps TJ

    更新日期：2010-11-01 00:00:00

  • Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis.

    abstract：:CAMAL (common antigen in myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood cells of persons with myeloid leukemias and shown in an immunoperoxidase slide test to be diagnostic of these leukemias. CAMAL has been shown to be inhibitory to myelopo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Leitch HA,Buskard N,Levy JG

    更新日期：1993-09-01 00:00:00

  • Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.

    abstract：:Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown promising response rates in relapsed and newly diagnosed MM, and bortezomib has recently been reported to inhibit OCLs. We here investigated t...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/leu.2008.174

    authors： Breitkreutz I,Raab MS,Vallet S,Hideshima T,Raje N,Mitsiades C,Chauhan D,Okawa Y,Munshi NC,Richardson PG,Anderson KC

    更新日期：2008-10-01 00:00:00

  • Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells.

    abstract：:We investigated the effect of ubenimex on the growth and differentiation of U937 cells, a histiocytic lymphoma cell line. Ubenimex is a dipeptide ((2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine) and an inhibitor of aminopeptidase B produced by Streptomyces olivoreticuli. Ubenimex inhibited the proliferation of U9...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Murata M,Kubota Y,Tanaka T,Iida-Tanaka K,Takahara J,Irino S

    更新日期：1994-12-01 00:00:00

  • A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission.

    abstract：:Graft-versus-host disease (GVHD) remains a major immunological complication after allogeneic bone marrow transplantation (allo-BMT), but also favors development of the beneficial graft-versus-leukemia (GVL) effect. A patient with AML-M4 (inv (16)) is described, who was given non-myeloablative remission reinduction the...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400810

    authors： Vandenberghe P,Verhoef GE,Emonds MP,Demuynck H,Zachée P,De Wolf-Peeters C,Decorte R,Cassiman JJ,Boogaerts MA

    更新日期：1997-10-01 00:00:00

  • Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4+ T cells.

    abstract：:On activation, umbilical cord blood (UCB) CD4(+) T cells demonstrate reduced expression of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), whereas maintaining equivalent interleukin-2 (IL-2) levels, as compared with adult peripheral blood (PB) CD4(+) T cells. Nuclear factor of activated T cel...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.234

    authors： Lesniewski ML,Haviernik P,Weitzel RP,Kadereit S,Kozik MM,Fanning LR,Yang YC,Hegerfeldt Y,Finney MR,Ratajczak MZ,Greco N,Paul P,Maciejewski J,Laughlin MJ

    更新日期：2008-12-01 00:00:00

  • Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

    abstract：:Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0334-3

    authors： Saenz DT,Fiskus W,Manshouri T,Mill CP,Qian Y,Raina K,Rajapakshe K,Coarfa C,Soldi R,Bose P,Borthakur G,Kadia TM,Khoury JD,Masarova L,Nowak AJ,Sun B,Saenz DN,Kornblau SM,Horrigan S,Sharma S,Qiu P,Crews CM,Versto

    更新日期：2019-06-01 00:00:00

  • Acute B-lymphocytic leukemia with L1 morphology: a report of two pediatric cases.

    abstract：:Two pediatric cases of acute lymphoblastic leukemia with L1 morphology who also demonstrated immunoglobulin on the leukemic cell surface are presented. The first patient's disease progressed on standard induction therapy, despite the presence of good prognostic features at presentation. The second patient has achieved...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Finlay JL,Borcherding W

    更新日期：1988-01-01 00:00:00

  • Induction treatment of acute promyelocytic leukemia using all-trans retinoic acid. Controversies about dosage, advantages and side-effect management.

    abstract：:All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) represents the leading example of targetted drugs for inducing an in vivo differentiation of malignancy (1,2). A fixed dose of 45 mg/m2/day was proposed for the treatment of patients (3), according to the results obtained by retinoic acid derivatives...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Dombret H,Castaigne S,Fenaux P,Chomienne C,Degos L

    更新日期：1994-01-01 00:00:00

  • Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.

    abstract：:We studied the differentiation profiles of B cell precursors (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the three major maturational BCP stages in BM. By correlating lineage-associated markers...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400732

    authors： Dworzak MN,Fritsch G,Fleischer C,Printz D,Fröschl G,Buchinger P,Mann G,Gadner H

    更新日期：1997-08-01 00:00:00

  • Selected pharmacologic characteristics of idarubicin and idarubicinol.

    abstract：:The pharmacology of ID and IDOL are of interest in light of the potential utility of ID in the treatment of adult and pediatric leukemia patients. Preclinical activity and cellular pharmacology of ID were suggestive of greater clinical activity when compared with several standard anthracyclines. Most intriguing were d...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Ames MM,Spreafico F

    更新日期：1992-01-01 00:00:00

  • KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

    abstract：:To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in Kruppel-like factor 2 (KLF2), a gene whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice. KLF2 mutation wa...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.330

    authors： Clipson A,Wang M,de Leval L,Ashton-Key M,Wotherspoon A,Vassiliou G,Bolli N,Grove C,Moody S,Escudero-Ibarz L,Gundem G,Brugger K,Xue X,Mi E,Bench A,Scott M,Liu H,Follows G,Robles EF,Martinez-Climent JA,Oscier D,Wa

    更新日期：2015-05-01 00:00:00

  • Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

    abstract：:Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 in...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.243

    authors： Teh TC,Nguyen NY,Moujalled DM,Segal D,Pomilio G,Rijal S,Jabbour A,Cummins K,Lackovic K,Blombery P,Thompson E,Ekert PG,Lessene G,Glaser SP,Huang DCS,Roberts AW,Guthridge MA,Wei AH

    更新日期：2018-02-01 00:00:00

  • Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox).

    abstract：:Schedule dependency of idarubicin (Ida) and doxorubicin (Dox) toxicity was investigated in vitro using the K562 human leukemia cell line. For Dox, repeated exposure to the IC30 (d x 3) resulted in comparable survival as single exposure to the total accumulative dose (20%). For Ida, repeated exposure to the IC30 (d x 3...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Minderman H,Buscaglia MD,Rustum YM

    更新日期：1994-08-01 00:00:00

  • Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

    abstract：:Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 fro...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/leu.2015.281

    authors： Gratwohl A,Pfirrmann M,Zander A,Kröger N,Beelen D,Novotny J,Nerl C,Scheid C,Spiekermann K,Mayer J,Sayer HG,Falge C,Bunjes D,Döhner H,Ganser A,Schmidt-Wolf I,Schwerdtfeger R,Baurmann H,Kuse R,Schmitz N,Wehmeier A,

    更新日期：2016-03-01 00:00:00

  • Quality assurance in RT-PCR-based BCR/ABL diagnostics--results of an interlaboratory test and a standardization approach.

    abstract：:Here we describe the results of an interlaboratory test for RT-PCR-based BCR/ABL analysis. The test was organized in two parts. The number of participating laboratories in the first and second part was 27 and 20, respectively. In the first part samples containing various concentrations of plasmids with the ela2, b2a2 ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401899

    authors： Burmeister T,Maurer J,Aivado M,Elmaagacli AH,Grünebach F,Held KR,Hess G,Hochhaus A,Höppner W,Lentes KU,Lübbert M,Schäfer KL,Schafhausen P,Schmidt CA,Schüler F,Seeger K,Seelig R,Thiede C,Viehmann S,Weber C,Wilhelm

    更新日期：2000-10-01 00:00:00

  • Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia.

    abstract：:Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT). In these patients, absence of PCR bcr-abl fusion transcripts confirmed the potency of donor leukocytes ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401144

    authors： Berthou C,Léglise MC,Herry A,Balcon D,Hardy E,Lessard M,Abgrall JF

    更新日期：1998-11-01 00:00:00

  • Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.

    abstract：:The mechanism by which aplidine, a marine natural product in early clinical development as an anticancer agent, induces cell growth inhibition and apoptosis has been investigated in the human leukemia cell line MOLT-4. This cell line is characterized not only by the ability to secrete VEGF, but also for the presence o...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402788

    authors： Broggini M,Marchini SV,Galliera E,Borsotti P,Taraboletti G,Erba E,Sironi M,Jimeno J,Faircloth GT,Giavazzi R,D'Incalci M

    更新日期：2003-01-01 00:00:00

  • Cancer increases risk of in-hospital death from COVID-19 in persons

    abstract：:The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent ri...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0986-7

    authors： Li Q,Chen L,Li Q,He W,Yu J,Chen L,Cao Y,Chen W,Di Wu,Dong F,Cai L,Ran Q,Li L,Liu Q,Ren W,Gao F,Wang H,Chen Z,Gale RP,Hu Y

    更新日期：2020-09-01 00:00:00

  • Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms.

    abstract：:Highly polymorphic tandemly repetitive DNA sequences provide powerful genetic markers for the identification of individuals by restriction fragment length polymorphisms (RFLP) even in close relatives. Over a three-year period, 61 consecutive patients from a single institution undergoing allogeneic bone marrow transpla...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Suttorp M,Schmitz N,Dreger P,Schaub J,Löffler H

    更新日期：1993-05-01 00:00:00